
Hester Bios Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
No
0 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Animal Healthcare division is growing rapidly, now contributing 42% to the top line, up from 30% last year, driven by increased vaccine sales (e.g., PPR and LSD vaccines).
- Vaccine business expected to increase as a percentage, though larger health products market will require more focus on health products for scale-up.
- LSD immunization in India seen as repeatable business with annual vaccination; potential market linked to 9 crore cattle vaccinated recently.
- African market growth is delayed due to economic and regulatory challenges but expected to pick up in 6-8 months; presence there positions Hester advantageously for future demand.
- New generation vaccines (e.g., next-gen Brucella, Classical Swine Fever, Lumpy Skin Disease) under development to drive future growth.
- Sales in pharma/trading products are currently one-time but could recur.
- Overall revenue growth supported by expanded sales force and wider product reach.
See what Hester Bios management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No significant new capital expenditure (capex) is expected on existing projects; majority of expenditure is already done, currently in regulatory approval stage.
- No mention of new fundraising through debt or equity for ongoing projects; the company feels well-covered financially for current projects.
- Any new projects requiring finances would be separately addressed; currently, no such announcements.
- Repurposing existing BSL-3 facility for vaccines will require nominal spend (estimated up to a couple of crores INR, possibly less than 50 lakhs INR), implying limited need for fresh funds.
- Overall, no indication of immediate or planned fundraising through debt or equity as per the current transcript.
See what Hester Bios management said on order book — free account, 30 seconds.
Capex plans
No- Majority of the existing capex for ongoing projects has been completed; remaining expenditure is not expected to be significant as per CFO Nikhil Jhanwar.
- Current focus is on regulatory approvals for completed capacity expansion, which will double overall vaccine manufacturing capacity.
- The BSL-3 laboratory, initially for COVID vaccine production, is being repurposed for other vaccines (human/animal) with nominal additional spend estimated to be around INR 0.5 to 2 crores.
- No significant new capital investment planned unless new projects arise.
- Company is working on four new vaccine developments, leveraging existing infrastructure.
- Strategic investment includes expanding into African markets despite short-term challenges, with backing from the Bill & Melinda Gates Foundation.
Track Hester Bios — get its next earnings analysis in your feed
How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Hester Bios rank in Pharmaceuticals & Biotechnology?
Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem